Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
27
×
national blog main
san francisco blog main
san francisco top stories
27
×
startups
27
×
life sciences
biotech
boston blog main
national top stories
new york blog main
new york top stories
boston top stories
san diego blog main
san diego top stories
detroit blog main
detroit top stories
raleigh-durham blog main
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
indiana blog main
indiana top stories
national
fda
investing
cancer
cancer immunotherapy
clinical trials
pfizer
san francisco
eli lilly
gene therapy
alzheimer's disease
merck
What
bio
roundup
drug
companies
startup
biotech
cancer
crispr
deal
develop
drugs
medicines
new
today
acquisitions
based
big
ceo
days
firm
gene
help
life
pfizer’s
pharmaceutical
sciences
years
ahead
alzheimer’s
amid
announced
asco
babies
biggest
bombast
business
buy
cash
caught
coronavirus
Language
unset
unknown
Current search:
startups
×
deals
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
4 years ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Auris Health Lands $220M to Expand Sales of Lung Testing Medical Robot
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Quest Analytics Buys Healthcare Compliance Software Firm BetterDoctor
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Fictiv Raises $15M To Connect Tech Innovators & Parts Manufacturers
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed